Vonoprazan–minocycline dual therapy as a first-line treatment of infection compared with empirical bismuth-containing quadruple therapy
Background: Increasing antibiotic resistance compromises therapeutic options for Helicobacter pylori ( H. pylori ) infection, especially in penicillin-allergic individuals. Objectives: This trial aimed to assess the efficacy and safety of 14-day vonoprazan–minocycline (VM) dual therapy against bismu...
Saved in:
| Main Authors: | Meng Li, Xiaolei Wang, Xinhong Dong, Guigen Teng, Yun Dai, Weihong Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-08-01
|
| Series: | Therapeutic Advances in Gastroenterology |
| Online Access: | https://doi.org/10.1177/17562848251366156 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of bismuth quadruple regimens containing minocycline and vonoprazan for eradication of Helicobacter pylori: Real‐world evidence
by: Qiyunna He, et al.
Published: (2024-05-01) -
Corrigendum to “Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori”
by: Lingyun Zhang, et al.
Published: (2021-01-01) -
Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysis
by: Xiao Li, et al.
Published: (2025-03-01) -
Fourteen-day vonoprazan-amoxicillin dual therapy versus 14-day bismuth-based quadruple therapy for treatment: a randomized clinical trial
by: Jin-Yan Zhang, et al.
Published: (2025-07-01) -
The importance of bismuth-containing quadruple therapy in Helicobacter pylori eradication in an era of increasing antibiotic resistance
by: Yi HU, et al.
Published: (2020-06-01)